RELMADA THERAPEUTICS, INC. (RLMD) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 2020 - 2022

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Relmada Therapeutics, Inc. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and growth rate from 2020 to 2022.
  • Relmada Therapeutics, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending September 30, 2022 was $166 M, a 129% increase year-over-year.
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2022 $166 M +$93.7 M +129% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $197 M Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $210 M Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $208 M +$103 M +97.3% Dec 31, 2021 10-Q 2022-11-10
Q3 2021 $72.7 M Sep 30, 2021 10-Q 2021-11-12
Q4 2020 $106 M Dec 31, 2020 10-K 2022-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.